Clinical Profile


Clinical efficacy across a range of patient types1

Safety Considerations1

ULTANE is contraindicated in patients with known or suspected genetic susceptibility to malignant hyperthermia or known or suspected sensitivity to sevoflurane or to other halogenated inhalational anesthetics. Use of ULTANE for more than 2 MAC-hours at flow rates of 1 to <2 L/min may be associated with a potential for renal injury, glycosuria, and proteinuria. Fresh gas flow rates <1 L/min are not recommended. KOH containing CO2 absorbents are not recommended for use with ULTANE. Patients may develop QT prolongation, perioperative hyperkalemia, excessive decreases in blood pressure, bradycardia, respiratory depression, seizures, and postoperative hepatic dysfunction or hepatitis with or without jaundice.

© 2022 AbbVie. All rights reserved.
ULTANE® and its design are registered trademarks of AbbVie Inc.
NIMBEX® and its design are trademarks of GlaxoSmithKline LLC, used under license by AbbVie Inc.
US-ULTA-220022 November 2022


AbbVie logo